Search results for "Protocol"

showing 10 items of 1808 documents

Evaluation of the psychometric properties of “the Norwegian screening test for dyslexia”

2018

The aim of this study was to develop and investigate the psychometric properties of a screening protocol for Norwegian students in upper secondary school. The protocol was designed to assess skills that are at stake in dyslexia. It was administered to 232 students. In the absence of a “gold standard,” comparisons were made between students who reported normal literacy skills (n = 184) and literacy problems (n = 48). Significant group differences were found across all areas. Logistic regression and receiver operating characteristic curve analyses demonstrated good discriminatory power. The screening protocol met the standards for reliability and validity. It has the potential to be a useful …

MalePsychometricsiltalukiotheritabilityLogistic regressionNorjaspellingDevelopmental and Educational Psychologykeskiasteen koulutusReliability (statistics)ta515SchoolsNorway05 social sciences050301 educationGeneral MedicineperiytyvyyslanguageFemaleyläkouluPsychologyupper secondary050104 developmental & child psychologyClinical psychologyAdolescentPsychometricseducationExperimental and Cognitive PsychologyNorwegianbehavioral disciplines and activitiesEducationYoung AdultepäjärjestysdyslexiamedicineHumansdysleksia0501 psychology and cognitive sciencesStudentsUpper secondary general schools (evening classes)reading (activity)screening testProtocol (science)Receiver operating characteristicGold standardDyslexiaReproducibility of Resultslukeminen (toiminta)medicine.diseaselanguage.human_languageBehavior Rating Scalelukihäiriöt0503 educationDyslexia
researchProduct

Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale

2002

Abstract Introduction: Platinum-based chemotherapy is the gold standard in advanced non-small cell lung cancer (NSCLC), although with relevant toxic effects. Both docetaxel (DCT) and gemcitabine (GEM) have shown activity as single agent in advanced NSCLC with a different toxicity profile and a lack of cross-resistance. Materials and methods: From April 2000 to May 2001, 47 consecutive patients were enrolled in a multicenter phase II trial. Main inclusion criteria included untreated patients with histologically confirmed NSCLC, age⩽70 years, stage IIIB/IV, Eastern Cooperative Oncology Group performance status (PS) 0–2, measurable disease, adequate hematologic, cardiac, hepatic and renal func…

MalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaCost ControlPaclitaxelSurvivalmedicine.medical_treatmentPhases of clinical researchDocetaxelNeutropeniaDeoxycytidineGastroenterologyDrug CostsCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansLung cancerAgedChemotherapybusiness.industryMiddle Agedmedicine.diseaseGemcitabineGemcitabineSurgeryTreatment OutcomeOncologyDocetaxelDisease ProgressionFemaleTaxoidsbusinessProgressive diseasemedicine.drugLung Cancer
researchProduct

A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with che…

2013

Abstract Introduction Tigatuzumab, a humanized monoclonal DR5 agonist antibody induces apoptosis in human cancer cell lines. The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-naive patients with metastatic/unresectable non-small cell lung cancer (NSCLC). Methods Patients with histologically or cytologically confirmed NSCLC stage IIIB/IV disease by RECIST (version 1.0) and ECOG-PS 0–1 were enrolled at 15 European sites. Patients received tigatuzumab or placebo intravenously with carboplatin/paclitaxel every 3 weeks (1 cycle) for up to 6 cycles. The primary end point was progression-free survival (PFS). Sec…

MalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaPaclitaxelmedicine.medical_treatmentPhases of clinical researchNeutropeniaAntibodies Monoclonal HumanizedPlaceboGastroenterologyDisease-Free SurvivalCarboplatinPlaceboschemistry.chemical_compoundDouble-Blind MethodCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisTigatuzumabLung cancerNeoplasm StagingChemotherapybusiness.industryMiddle Agedmedicine.diseaseCarboplatinSurgeryEuropeReceptors TNF-Related Apoptosis-Inducing LigandOncologychemistryPaclitaxelFemalebusinessLung Cancer
researchProduct

NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri eve…

2021

OBJECTIVE: The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects. Chemotherapy-induced nausea and vomiting (CINV) are amongst the most troublesome side effects that impair patients’ adherence to treatments and their quality of life (QoL). NEPA (Akynzeo®), is an oral fixed-dose combination of netupitant [a neurokinin-1 receptor antagonist (NK1RA), 300 mg] and palonosetron [(5-hydroxytryptamine (serotonin or 5HT) type3 receptor antagonist (5HT3RA), 0.5 mg] which has been shown to be effective in preventing CINV. PATIENTS AND METHODS: This prospective study started before…

MalePyridinesVomitingCINVLeucovorinCOVID-19NauseaMiddle AgedIrinotecanColorectal cancerBevacizumabOxaliplatinPalonosetronNetupitantAntineoplastic Combined Chemotherapy ProtocolsAntiemeticsHumansEmetogenic chemotherapyFemaleFluorouracilProspective StudiesColorectal NeoplasmsPandemicsAdvanced pancreatic cancerAgedEuropean review for medical and pharmacological sciences
researchProduct

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

2019

Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes of regorafenib as second-line treatment for HCC recurrence after liver transplantation (LT). This is a retrospective, multicenter, international study including regorafenib-treated LT patients (2015-2018), with analysis of baseline characteristics and evolutionary events during sorafenib/regorafenib treatment. Twenty-eight LT patients (57 years, 7% cirrhotics, 54% performance status 1) were included. Median time from LT to regorafenib initiation was 3.9 (1.1-18.5) years; media…

MalePyridinesmedicine.medical_treatment030230 surgeryLiver transplantationchemotherapyGastroenterologychemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyPharmacology (medical)Liver NeoplasmsMiddle AgedSorafenibPrognosisRecurrent Hepatocellular Carcinomaside effectsHepatocellular carcinomaFemalemedicine.drugSorafenibAdultmedicine.medical_specialtyCarcinoma Hepatocellularcancer/malignancy/neoplasiaclinical research/practice03 medical and health sciencesYoung AdultInternal medicineRegorafenibmedicineHumansAdverse effectAgedRetrospective StudiesTransplantationdrug interactionPerformance statusbusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationLiver TransplantationchemistryDrug Resistance NeoplasmNeoplasm Recurrence Localpharmacologybusinessliver transplantation/hepatologyFollow-Up Studies
researchProduct

Design of a randomized controlled trial of physical training and cancer ( Phys-Can) the impact of exercise intensity on cancer related fatigue, quali…

2017

Background: Cancer-related fatigue is a common problem in persons with cancer, influencing health-related quality of life and causing a considerable challenge to society. Current evidence supports the beneficial effects of physical exercise in reducing fatigue, but the results across studies are not consistent, especially in terms of exercise intensity. It is also unclear whether use of behaviour change techniques can further increase exercise adherence and maintain physical activity behaviour. This study will investigate whether exercise intensity affects fatigue and health related quality of life in persons undergoing adjuvant cancer treatment. In addition, to examine effects of exercise …

MaleQuality of lifeCancer Researchmedicine.medical_specialtyActivities of daily livingBreast NeoplasmsPhysical exerciselcsh:RC254-282law.inventionStudy Protocol03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationQuality of life (healthcare)Cancer SurvivorsRandomized controlled trialEndurance traininglawBehaviour change techniquesGeneticsmedicineHumans030212 general & internal medicineCancer-related fatigueFatigueCancerCancer och onkologibusiness.industryCancer; Physical exercise; Behaviour change techniques; Fatigue; Biological mechanism; Quality of life; Randomized controlled trialProstatic NeoplasmsPhysical exerciseBiological mechanismlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensExercise TherapyMoodOncologyPhysical FitnessRandomized controlled trial030220 oncology & carcinogenesisCancer and OncologyExercise intensityPhysical therapyFemalemedicine.symptomColorectal Neoplasmsbusiness
researchProduct

Single-dose Palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving mode…

2011

PURPOSE: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT(3)) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids. METHODS: Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting …

MaleQuinuclidinesmedicine.medical_treatmentCINVCHOPGastroenterologyDexamethasoneSettore MED/15 - Malattie Del SangueAntineoplastic Combined Chemotherapy ProtocolsSerotonin 5-HT3 Receptor AntagonistsProspective StudiesAged 80 and overLymphoma Non-HodgkinPalonosetronNauseaMiddle AgedEmesisPalonosetronTreatment OutcomeOncologyAnesthesiaCHOP CINV Emesis Nausea NHL PalonosetronVomitingFemaleOriginal Articlemedicine.symptomCHOP-CINV; emesis; nausea; NHL; Palonosetronmedicine.drugAdultmedicine.medical_specialtyVomitingNauseamedicine.drug_classNHLYoung AdultInternal medicinemedicineHumansAntiemeticGlucocorticoidsAgedChemotherapybusiness.industryIsoquinolinesmedicine.diseaseNon-Hodgkin's lymphomaAntiemeticsbusinessCHOPChemotherapy-induced nausea and vomiting
researchProduct

Treatment of soft tissue sarcoma in childhood and adolescence: A report of the german cooperative soft tissue sarcoma study

1992

Background In the first German soft tissue sarcoma (STS) study, CWS-81, 344 patients younger than 19 years of age who had previously untreated soft tissue sarcoma were studied. For this analysis, there were 218 patients with chemosensitive STS (Group A: rhabdomyosarcoma [RMS], synovial sarcoma, extraosseous Ewing sarcoma, leiomyosarcoma, undifferentiated sarcoma, and malignant peripheral neuroectodermal tumor) who could be studied for a minimum potential follow-up time of 6 years. Methods A staging system based on the postoperative extent of the disease was used. The chemotherapy for Stage I-III disease consisted of vincristine, dactinomycin, cyclophosphamide, and doxorubicin (VACA). Patien…

MaleReoperationLeiomyosarcomaCancer Researchmedicine.medical_specialtyVincristineAdolescentmedicine.medical_treatmentSoft Tissue NeoplasmsGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChildRhabdomyosarcomaCyclophosphamideSurvival rateNeoplasm StagingChemotherapybusiness.industrySoft tissue sarcomaSarcomaPrognosismedicine.diseaseCombined Modality TherapySurvival AnalysisSynovial sarcomaSurgeryOncologyChemotherapy AdjuvantDoxorubicinVincristineChild PreschoolDactinomycinRegression AnalysisFemaleSarcomabusinessFollow-Up Studiesmedicine.drugCancer
researchProduct

MOBIlity assessment with modern TEChnology in older patients’ real-life by the General Practitioner: the MOBITEC-GP study protocol

2019

Abstract Background Mobility limitations in older adults are associated with poor clinical outcomes including higher mortality and disability rates. A decline in mobility (including physical function and life-space) is detectable and should be discovered as early as possible, as it can still be stabilized or even reversed in early stages by targeted interventions. General practitioners (GPs) would be in the ideal position to monitor the mobility of their older patients. However, easy-to-use and valid instruments for GPs to conduct mobility assessment in the real-life practice setting are missing. Modern technologies such as the global positioning system (GPS) and inertial measurement units …

MaleResearch designTechnologyAginghealth promotionValiditymonitorointismartphoneWalking speedStudy Protocol0302 clinical medicineHealth carespatial behaviorMedicine and Health Sciences030212 general & internal medicine910 Geography & travelgeneral practicegeographic information systemslcsh:Public aspects of medicineGeographic information systemsMobile ApplicationsMobility limitationkävely10122 Institute of GeographyResearch DesignGlobal Positioning SystemFemaleSmartphonePublic HealthGeneral practiceikääntyneetmedicine.medical_specialtymultimorbidityMonitoring AmbulatoryInertial sensorswalking speedterveyden edistäminenmobility limitation03 medical and health sciencesPhysical medicine and rehabilitationGeneral PractitionersInertial measurement unitliikuntakykymedicineHumansGeriatric AssessmentAgedProtocol (science)business.industryagingEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthReproducibility of ResultsMultimorbiditylcsh:RA1-12702739 Public Health Environmental and Occupational HealthPatient Acceptance of Health Careinertial sensorsälypuhelimetPreferred walking speedikääntyminenSpatial behaviorMobility LimitationyleislääkäritsatelliittipaikannusHealth promotionbusiness030217 neurology & neurosurgeryBMC Public Health
researchProduct

Design considerations of a randomized clinical trial on a cognitive behavioural intervention using communication and information technologies for man…

2013

Background Psychological treatments have been successful in treating chronic low back pain (CLBP). However, the effect sizes are still modest and there is room for improvement. A way to progress is by enhancing treatment adherence and self-management using information and communication technologies (ICTs). Therefore, the objective of this study was to design a trial investigating the short- and long-term efficacy of cognitive behavioural treatment (CBT) for CLBP using or not ICTs. A secondary objective of this trial will be to evaluate the influence of relevant variables on treatment response. Possible barriers in the implementation of CBT with and without ICT will also be investigated. Met…

MaleResearch designmedicine.medical_specialtymedicine.medical_treatmentCognitive behavioural therapyInformation and communication technologiesbehavioral disciplines and activitiesHealth informaticslaw.inventionDisability EvaluationStudy ProtocolPhysical medicine and rehabilitationRheumatologyRandomized controlled triallawparasitic diseasesmedicineHumansPain ManagementLow back painOrthopedics and Sports MedicineRehabilitationCognitive Behavioral Therapybusiness.industryCatastrophizationCommunicationCognitionLow back painResearch DesignSpainCognitive therapyPhysical therapyPatient ComplianceAnxietyFemalemedicine.symptombusinessAttitude to HealthPhysical therapyMedical InformaticsBMC Musculoskeletal Disorders
researchProduct